Eloxx Pharmaceuticals, Inc.
ELOX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001035354
No open-market purchases or sales by Eloxx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Eloxx Pharmaceuticals, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 18 | 4 | −14 |
| Shares | 520.9K | 91.0K | −429.9K (−82.5%) |
| Value | $2.50M | $109.0K | −$2.40M (−95.6%) |
New holders (0)
Institutions that held Eloxx Pharmaceuticals, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
None.
Sold out (14)
Institutions that held Eloxx Pharmaceuticals, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Armistice Capital, LLC | 275,000 | $1.32M |
| Silverarc Capital Management, LLC | 54,075 | $260.1K |
| American Financial Group Inc | 37,000 | $178.0K |
| Vanguard Group Inc | 20,786 | $100.0K |
| Geode Capital Management, LLC | 19,588 | $93.3K |
| Atom Investors LP | 10,638 | $51.2K |
| BlackRock Inc. | 8,870 | $42.7K |
| Tower Research Capital LLC (TRC) | 1,830 | $8.80K |
| Wells Fargo & Company | 1,172 | $5.64K |
| Royal Bank of Canada | 526 | $3.00K |
| UBS Group AG | 291 | $1.40K |
| Morgan Stanley | 79 | $380 |
| Group One Trading, L.P. | 4 | $19 |
| JPMorgan Chase & Co | 1 | $5 |